Rigel Pharmaceuticals RIGL Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue recognized by Product | |||||
| Delivery of drug supplies, royalties and others | $19.05M-6.5% | $20.38M+78.5% | $11.41M+87.3% | $6.09M+84.7% | |
| Discounts and allowances | -$77.98M-19.9% | -$65.02M-52.0% | -$42.76M-34.5% | -$31.81M-75.0% | |
| Gross product sales | $309.96M+47.7% | $209.92M+42.7% | $147.06M+35.5% | $108.52M+33.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Rigel Pharmaceuticals break its business down?
- Rigel Pharmaceuticals (RIGL) reports revenue recognized by product across 4 parts — Delivery of drug supplies, royalties and others, Development Milestones, Discounts and allowances and Gross product sales. Each is extracted from the segment footnotes and tracked over time.
- Where does Rigel Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Rigel Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
